Повторная лучевая терапия на фоне приема бевацизумаба в лечении рецидивов глиобластомы

Повторная лучевая терапия на фоне приема бевацизумаба в лечении рецидивов глиобластомы

Автор: Белоконь С.В., Гулидов И.А., Гоголин Д.В., Медведева К.Е., Иванов С.А., Каприн А.Д.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 1 т.23, 2024 года.

Бесплатный доступ

Введение. Глиобластома остается заболеванием с плохим прогнозом. Ввиду высокой агрессивности опухоли, несмотря на комплексный подход к лечению заболевания, практически неизбежен рецидив. До сих пор не существует единого стандарта лечения рецидивов глиобластомы, многие руководства рекомендуют ведение данных пациентов в рамках клинических исследований. Имеется множество подходов, таких как хирургическое вмешательство, лучевая терапия, системная или локальная химиотерапия или лечение таргетными препаратами, различные стратегии иммунотерапии, применение низкоинтенсивных среднечастотных электрических полей, а также их комбинации. Сочетание двух неинвазивных методик: повторной лучевой терапии и таргетной терапии бевацизумабом, остается наиболее часто применяемым подходом у данной группы пациентов, потенциал которого до конца не раскрыт. Цель исследования - анализ литературных данных по использованию повторной лучевой терапии с бевацизумабом в качестве лечебной опции у пациентов с глиобластомой. Материал и методы. Поиск литературы производился в системах Medline, Cochrane Library, E-library, Scopus, PubMed и Google Scholar.

Еще

Глиобластома, повторная лучевая терапия, протонная терапия, таргетная терапия, рецидив высокозлокачественной глиомы

Короткий адрес: https://sciup.org/140303741

IDR: 140303741   |   DOI: 10.21294/1814-4861-2024-23-1-142-154

Список литературы Повторная лучевая терапия на фоне приема бевацизумаба в лечении рецидивов глиобластомы

  • Grochans S., Cybulska A.M., Simińska D., Korbecki J., Kojder K., Chlubek D., Baranowska-Bosiacka I. Epidemiology of Glioblastoma Multiforme - Literature Review. Cancers (Basel). 2022; 14(10): 2412. https://doi.org/10.3390/cancers14102412.
  • Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., Curschmann J., Janzer R.C., Ludwin S.K., Gorlia T., Allgeier A., Lacombe D., Cairncross J.G., Eisenhauer E., Mirimanoff R.O.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-96. https://doi.org/10.1056/NEJMoa043330.
  • Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Nikšić M., Bonaventure A., Valkov M., Johnson C.J., Estève J., Ogunbiyi O.J., Azevedo E Silva G., Chen W.Q., Eser S., Engholm G., Stiller C.A., Monnereau A., Woods R.R., Visser O., Lim G.H., Aitken J., Weir H.K., Coleman M.P.; CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125): 1023-75. https://doi.org/10.1016/S0140-6736(17)33326-3.
  • Ostrom Q.T., Price M., Neff C., Cioffi G., Waite K.A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. Neuro Oncol. 2022; 24(s5):1-95. https://doi.org/10.1093/neuonc/noac202.
  • Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5): 459-66. https://doi.org/10.1016/S1470-2045(09)70025-7.
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Central Nervous System Cancers [Internet]. Version 1.2023 - March 24, 2023, nccn.org. [cited 2023 Dec 19]. URL: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
  • De Bonis P., Anile C., Pompucci A., Fiorentino A., Balducci M., Chiesa S., Lauriola L., Maira G., Mangiola A. The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg. 2013; 115(1): 37-43. https://doi.org/10.1016/j.clineuro.2012.04.005.
  • van Nifterik K.A., Elkhuizen P.H., van Andel R.J., Stalpers L.J., Leenstra S., Lafleur M.V., Vandertop W.P., Slotman B.J., Hulsebos T.J., Sminia P. Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor? J Neurosurg. 2006; 105(5): 739-44. https://doi.org/10.3171/jns.2006.105.5.739.
  • Weller M., van den Bent M., Preusser M., Le Rhun E., Tonn J.C., Minniti G., Bendszus M., Balana C., Chinot O., Dirven L., French P., Hegi M.E., Jakola A.S., Platten M., Roth P., Rudà R., Short S., Smits M., Taphoorn M.J.B., von Deimling A., Westphal M., Soffietti R., Reifenberger G., Wick W. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021; 18(3): 170-86. https://doi.org/10.1038/s41571-020-00447-z. Erratum in: Nat Rev Clin Oncol. 2022; 19(5): 357-8.
  • Sminia P., Mayer R. External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain. Cancers (Basel). 2012; 4(2): 379-99. https://doi.org/10.3390/cancers4020379.
  • Minniti G., Niyazi M., Alongi F., Navarria P., Belka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021; 16(1): 36. https://doi.org/10.1186/s13014-021-01767-9.
  • Scoccianti S., Francolini G., Carta G.A., Greto D., Detti B., Simontacchi G., Visani L., Baki M., Poggesi L., Bonomo P., Mangoni M., Desideri I., Pallotta S., Livi L. Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions. Crit Rev Oncol Hematol. 2018; 126: 80-91. https://doi.org/10.1016/j.critrevonc.2018.03.024.
  • Kazmi F., Soon Y.Y., Leong Y.H., Koh W.Y., Vellayappan B. Reirradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol. 2019; 142(1): 79-90. https://doi.org/10.1007/s11060-018-03064-0.
  • Marwah R., Xing D., Squire T., Soon Y.Y., Gan H.K., Ng S.P. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity. J Neurooncol. 2023; 164(3): 505-24. https://doi.org/10.1007/s11060-023-04441-0.
  • Kiseleva V., Gordon K., Vishnyakova P., Gantsova E., Elchaninov A., Fatkhudinov T. Particle Therapy: Clinical Applications and Biological Effects. Life (Basel). 2022; 12(12): 2071. https://doi.org/10.3390/life12122071.
  • Patyal B. Dosimetry aspects of proton therapy. Technol Cancer Res Treat. 2007; 6(4s): 17-23. https://doi.org/10.1177/15330346070060S403.
  • Saeed A.M., Khairnar R., Sharma A.M., Larson G.L., Tsai H.K., Wang C.J., Halasz L.M., Chinnaiyan P., Vargas C.E., Mishra M.V. Clinical Outcomes in Patients with Recurrent Glioblastoma Treated with Proton Beam Therapy Reirradiation: Analysis of the Multi-Institutional Proton Collaborative Group Registry. Adv Radiat Oncol. 2020; 5(5): 978-83. https://doi.org/10.1016/j.adro.2020.03.022.
  • Gulidov I., Gordon K., Semenov A., Gogolin D., Lepilina O., Golovanova O., Dujenko S., Medvedeva K., Koryakin S., Ivanov S., Kaprin A. Proton re-irradiation of unresectable recurrent brain gliomas: clinical outcomes and toxicity. J BUON. 2021; 26(3): 970-6.
  • Gulidov I.A., Gordon K.B., Gogolin D.V., Mardynskii Yu.S., Lepilina O.G., Neledov D.V., Galkin V.N., Kaprin A.D. Povtornoe obluchenie intrakranial'nykh opukholei aktivnym skaniruyushchim puchkom protonov. Sibirskii onkologicheskii zhurnal. 2017; 16(5): 63-70. https://doi.org/10.21294/1814-4861-2017-16-5-63-70.
  • Medvedeva K.E., Gulidov I.A., Mardynskii Yu.S., Gogolin D., Gordon K.B., Semenov A.V., Lepilina O.G., Kaprin A.D., Kostin A.A., Ivanov S.A. Vozmozhnosti protonnoi terapii pri povtornom obluchenii retsidivnykh gliom. Meditsinskaya radiologiya i radiatsionnaya bezopasnost'. 2019; 64(2): 70-4. https://doi.org/10.12737/article_5ca607bf670c97.49055999.
  • Simon J.M., Cornu P., Boisserie G., Hasboun D., Tep B., Hardiman C., Valery C.A., Delattre J.Y., Dormont D., Baillet F., Mazeron J.J. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys. 2002; 53(1): 67-74. https://doi.org/10.1016/s0360-3016(01)02804-8.
  • Gutin P.H., Phillips T.L., Wara W.M., Leibel S.A., Hosobuchi Y., Levin V.A., Weaver K.A., Lamb S. Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg. 1984; 60(1): 61-8. https://doi.org/10.3171/jns.1984.60.1.0061.
  • Chan T.A., Weingart J.D., Parisi M., Hughes M.A., Olivi A., Borzillary S., Alahakone D., Detorie N.A., Wharam M.D., Kleinberg L. Treatment of recurrent glioblastoma multiforme with GliaSite brachy-therapy. Int J Radiat Oncol Biol Phys. 2005; 62(4): 1133-9. https://doi.org/10.1016/j.ijrobp.2004.12.032.
  • Takano S., Yamashita T., Ohneda O. Molecular therapeutic targets for glioma angiogenesis. J Oncol. 2010. https://doi.org/10.1155/2010/351908.
  • Bruna A., Darken R.S., Rojo F., Ocaña A., Peñuelas S., Arias A., Paris R., Tortosa A., Mora J., Baselga J., Seoane J. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007; 11(2): 147-60. https://doi.org/10.1016/j.ccr.2006.11.023.
  • Lin J.L., Wang M.J., Lee D., Liang C.C., Lin S. Hypoxia-inducible factor-1alpha regulates matrix metalloproteinase-1 activity in human bone marrow-derived mesenchymal stem cells. FEBS Lett. 2008; 582(17): 2615-9. https://doi.org/10.1016/j.febslet.2008.06.033.
  • Phillips H., Armani M., Stavrou D., Ferrara N., Westphal M. Intense focal expression of vascular endothelial growth-factor messenger-RNA in human intracranial neoplasms - association with regions of necrosis. Int J Oncol. 1993; 2(6): 913-9. https://doi.org/10.3892/ijo.2.6.913.
  • Zang J., Li C., Zhao L.N., Shi M., Zhou Y.C., Wang J.H., Li X. Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis. Head Neck. 2013; 35(10): 1507-14. https://doi.org/10.1002/hed.23156.
  • Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801): 249-57. https://doi.org/10.1038/35025220.
  • Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., Munn L.L., Jain R.K. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6): 553-63. https://doi.org/10.1016/j.ccr.2004.10.011.
  • Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006; 5: 67. https://doi.org/10.1186/1476-4598-5-67.
  • Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., Shi Q., McLendon R.E., Bigner D.D., Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006; 66(16): 7843-8. https://doi.org/10.1158/0008-5472.CAN-06-1010.
  • Friedman H.S., Prados M.D., Wen P.Y., Mikkelsen T., Schiff D., Abrey L.E., Yung W.K., Paleologos N., Nicholas M.K., Jensen R., Vredenburgh J., Huang J., Zheng M., Cloughesy T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28): 4733-40. https://doi.org/10.1200/JCO.2008.19.8721.
  • Lombardi G., Pambuku A., Bellu L., Farina M., Della Puppa A., Denaro L., Zagonel V. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2017; 111: 94-102. https://doi.org/10.1016/j.critrevonc.2017.01.018.
  • McBain C., Lawrie T.A., Rogozińska E., Kernohan A., Robinson T., Jefferies S. Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev. 2021; 5(1). https://doi.org/10.1002/14651858.CD013579.pub2.
  • Zhang T., Xin Q., Kang J.M. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021; 25(21): 6480-91. https://doi.org/10.26355/eurrev_202111_27092.
  • Kazmi F., Soon Y.Y., Leong Y.H., Koh W.Y., Vellayappan B. Reirradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis. J Neurooncol. 2019; 142(1): 79-90. https://doi.org/10.1007/s11060-018-03064-0.
  • Combs S.E., Niyazi M., Adeberg S., Bougatf N., Kaul D., Fleischmann D.F., Gruen A., Fokas E., Rödel C.M., Eckert F., Paulsen F., Oehlke O., Grosu A.L., Seidlitz A., Lattermann A., Krause M., Baumann M., Guberina M., Stuschke M., Budach V., Belka C., Debus J., Kessel K.A. Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK). Cancer Med. 2018; 7(5): 1742-9. https://doi.org/10.1002/cam4.1425.
  • Møller S., Munck Af Rosenschöld P., Costa J., Law I., Poulsen H.S., Engelholm S.A., Engelholm S. Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial. Radiother Oncol. 2017; 125(2): 223-7. https://doi.org/10.1016/j.radonc.2017.09.039.
  • Moeller B.J., Cao Y., Li C.Y., Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004; 5(5): 429-41. https://doi.org/10.1016/s1535-6108(04)00115-1.
  • Heath V.L., Bicknell R. Anticancer strategies involving the vasculature. Nat Rev Clin Oncol. 2009; 6(7): 395-404. https://doi.org/10.1038/nrclinonc.2009.52.
  • Gutin P.H., Iwamoto F.M., Beal K., Mohile N.A., Karimi S., Hou B.L., Lymberis S., Yamada Y., Chang J., Abrey L.E. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009; 75(1): 156-63. https://doi.org/10.1016/j.ijrobp.2008.10.043.
  • Fleischmann D.F., Jenn J., Corradini S., Ruf V., Herms J., Forbrig R., Unterrainer M., Thon N., Kreth F.W., Belka C., Niyazi M. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma. Radiother Oncol. 2019; 138: 99-105. https://doi.org/10.1016/j.radonc.2019.06.009.
  • Kreisl T.N., Kim L., Moore K., Duic P., Royce C., Stroud I., Garren N., Mackey M., Butman J.A., Camphausen K., Park J., Albert P.S., Fine H.A. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009; 27(5): 740-5. https://doi.org/10.1200/JCO.2008.16.3055.
  • Kirkpatrick J.P., Meyer J.J., Marks L.B. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008; 18(4): 240-3. https://doi.org/10.1016/j.semradonc.2008.04.005.
  • Cuneo K.C., Vredenburgh J.J., Sampson J.H., Reardon D.A., Desjardins A., Peters K.B., Friedman H.S., Willett C.G., Kirkpatrick J.P. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012; 82(5): 2018-24. https://doi.org/10.1016/j.ijrobp.2010.12.074.
  • Park K.J., Kano H., Iyer A., Liu X., Niranjan A., Flickinger J.C., Lieberman F.S., Lunsford L.D., Kondziolka D. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. J Neurooncol. 2012; 107(2): 323-33. https://doi.org/10.1007/s11060-011-0744-9.
  • Guan Y., Xiong J., Pan M., Shi W., Li J., Zhu H., Gong X., Li C., Mei G., Liu X., Pan L., Dai J., Wang Y., Wang E., Wang X. Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience. BMC Cancer. 2021; 21(1): 123. https://doi.org/10.1186/s12885-021-07856-y.
  • Morris S.L., Zhu P., Rao M., Martir M., Zhu J.J., Hsu S., Ballester L.Y., Day A.L., Tandon N., Kim D.H., Shepard S., Blanco A., Esquenazi Y. Gamma Knife Stereotactic Radiosurgery in Combination with Bevacizumab for Recurrent Glioblastoma. World Neurosurg. 2019; 127: 523-33. https://doi.org/10.1016/j.wneu.2019.03.193.
  • Hundsberger T., Brügge D., Putora P.M., Weder P., Weber J., Plasswilm L. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neurooncol. 2013; 112(1): 133-9. https://doi.org/10.1007/s11060-013-1044-3.
  • Schnell O., Thorsteinsdottir J., Fleischmann D.F., Lenski M., Abenhardt W., Giese A., Tonn J.C., Belka C., Kreth F.W., Niyazi M. Reirradiation strategies in combination with bevacizumab for recurrent malignant glioma. J Neurooncol. 2016; 130(3): 591-9. https://doi.org/10.1007/s11060-016-2267-x.
  • Youland R.S., Lee J.Y., Kreofsky C.R., Brown P.D., Uhm J.H., Laack N.N. Modern reirradiation for recurrent gliomas can safely delay tumor progression. Neurooncol Pract. 2018; 5(1): 46-55. https://doi.org/10.1093/nop/npx014.
  • Chan J., Jayamanne D., Wheeler H., Khasraw M., Wong M., Kastelan M., Guo L., Back M. The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma. Clin Transl Radiat Oncol. 2020; 22: 33-9. https://doi.org/10.1016/j.ctro.2020.03.005.
  • Helis C.A., Prim S.N., Cramer C.K., Strowd R., Lesser G.J., White J.J., Tatter S.B., Laxton A.W., Whitlow C., Lo H.W., Debinski W., Ververs J.D., Black P.J., Chan M.D. Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma. Neurooncol Pract. 2022; 9(5): 390-401. https://doi.org/10.1093/nop/npac032.
  • Tsien C.I., Pugh S.L., Dicker A.P., Raizer J.J., Matuszak M.M., Lallana E.C., Huang J., Algan O., Deb N., Portelance L., Villano J.L., Hamm J.T., Oh K.S., Ali A.N., Kim M.M., Lindhorst S.M., Mehta M.P. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol. 2023; 41(6): 1285-95. https://doi.org/10.1200/JCO.22.00164.
  • Cuncannon M., Wong M., Jayamanne D., Guo L., Cove N., Wheeler H., Back M. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma. BMC Cancer. 2019; 19(1): 445. https://doi.org/10.1186/s12885-019-5678-1.
  • Modh A., Bergman D., Schultz L., Snyder J., Mikkelsen T., Ryu S., Siddiqui M.S., Walbert T. RTHP-06. Randomized prospective trial of stereotactic radiosurgery versus chemotherapy for recurrent malignant glioma after second-line chemotherapy. Neuro Oncol. 2018; 20(6). https://doi.org/10.1093/neuonc/noy148.938.
  • Tsien C., Pugh S., Dicker A.P., Raizer J.J., Matuszak M.M., Lallana E., Huang J., Algan O., Taylor N., Portelance L., Villano J., Hamm J., Oh K.S., Ali A.N., Kim M.M., Lindhorst S., Mehta M.P. Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and RT plan quality report. Int J Radiat Oncol Biol Phys. 2019; 105(1): 78. https://doi.org/10.1016/j.ijrobp.2019.06.539.
  • Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423): 841-4. https://doi.org/10.1038/362841a0.
  • Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706): 58-62. https://doi.org/10.1126/science.1104819.
  • Duda D.G., Jain R.K., Willett C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007; 25(26): 4033-42. https://doi.org/10.1200/JCO.2007.11.3985.
  • Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11(1): 69-82. https://doi.org/10.1016/j.ccr.2006.11.020.
  • Gilbertson R.J., Rich J.N. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007; 7(10): 733-6. https://doi.org/10.1038/nrc2246.
  • Matsko M.V., Matsko E.D. Neiroonkologiya, 2021. Kratkii analiz novoi klassifikatsii Vsemirnoi organizatsii zdravookhrane-niya opukholei tsentral'noi nervnoi sistemy. Vestnik Sankt-Peterburgskogo universiteta. Meditsina. 2022; 17(2): 88-100. https://doi.org/10.21638/spbu11.2022.202.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp